AstraZeneca to buy Bristol out of diabetes venture for up to $4.1 billion
Thursday, 19 December 2013
The Swedish – British pharmaceutical firm, AstraZeneca has agreed
to buy Bristol-Myers Squibb's stake in the companies' diabetes
joint venture for up to $4.1 billion in a deal that will help return
the group to growth, sending its shares to a new high.
According to reports from Reuters, AstraZeneca said on Thursday that it
would pay Bristol an initial $2.7 billion plus up to $1.4 billion in
additional regulatory and sales-related payments.
Detail and more reports from Reuters
Did you spot any error(s) or had any problem with the above article. Please contact us